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Background: Healthcare professional’s knowledge and attitudes to adverse drug reaction (ADR) and ADR reporting
play vital role to report any cases of ADR. Positive attitudes may favour ADR reporting by healthcare professionals.
This study was aimed to investigate the attitudes towards and ways to improve adverse drug reaction (ADR)
reporting among healthcare professionals working at four Regional Pharmacovigilance Centres (RPCs) of Nepal.
Methods: A cross sectional study was done by survey using a self-administered structured questionnaire. The
questionnaire was distributed to 450 healthcare professionals working at four RPCs.
Results: The overall response rate was 74.0%. There were 74.8% of healthcare professionals who had seen patient
experiencing an ADR; however, only 20.1% had reported. Reporting form not available (48.1%) and other colleagues
not reporting ADR cases (46.9%) would significantly discourage the ADR reporting among healthcare professionals
working at four RPCs. Healthcare professionals perceived that seriousness of the reaction (75.6%); unusual reaction
(64.6%); reaction to new product (71.2%); new reaction to existing product (70.2%); and confidence in diagnosis of
ADR (60.8%) were important factors on the decision to report ADR. Awareness among healthcare professionals
(85.9%), training (76.0%), collaboration (67.0%), and involve pharmacist for ADR reporting (63.1%) were mostly
recognized ways to improve reporting. Regular newsletter on current awareness in drug safety (71.2%), information
on new ADR (65.8%), and international drug safety information (64.0%) were the identified feedbacks they would
like to receive from the Nepal pharmacovigilance programme.
Conclusion: Healthcare professionals working at four RPCs of Nepal have positive attitudes towards ADR reporting.
Awareness among healthcare professionals, training and collaboration would likely improve reporting provided they
would receive appropriate feedback from the national pharamcovigilance programme.
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Spontaneous reporting system (SRS) still remains as the
most common method to report adverse drug reaction
(ADR) even though under reporting is estimated higher
than 90–95% [1-4]. Healthcare professionals are the
primary reporter of the ADR cases either to national
centre or to Pharma Company. There are different fac-
tors which encourage healthcare professionals to report
ADRs. Among all, healthcare professionals’ knowledge
about and attitudes towards ADR and ADR reporting
debate more frequently as an influential factors [5-8].
Reporting of each and every cases of ADR is important;* Correspondence: pramote.tra@mahidol.ac.th
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reproduction in any medium, provided the orhowever, reporting of previously unknown ADR, rare
ADR and serious unlabeled ADR is more important to
generate new signal and new knowledge. Healthcare pro-
fessionals are reluctant to report ADR when the ADR is
common, too trivial and uncertainty about the associ-
ation [9-11]. But it is interesting that some healthcare
professionals especially doctors report ADR because of
their professional interest to inform others [12]. Overall,
knowledge about and attitudes towards ADR plays vital
role in terms of ADR reporting.
In Nepal, ADR reporting is not mandatory for health-
care professionals. The Department of Drug Administra-
tion (DDA), the national drug regulatory authority, was
established in 1979 to enforce the Drug Act 1978. After
its establishment it had banned several drugs and itsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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potential toxicity, doubtful efficacy, and potential for ir-
rational use [13]. Though the need of pharmacovigilance
has been identified early; however, it is started several
years after its establishment. The DDA took the initia-
tives to set up a pharmacovigilance programme in 2002.
In 2004, DDA was designated as a National Pharmacovi-
gilance Centre (NPC). Two years later, it became full
member of World Health Organization (WHO) collab-
orating Centre for International Drug Monitoring. Im-
mediately after its establishment, NPC facilitated the
operation of Regional Pharmacovigilance Centre (RPC)
in different part of the country. Currently there are six
RPCs operating in the country based on Kathmandu,
Lalitpur, Pokhara and Biratnagar. Though the NPC is
encouraging the RPCs to report more ADR, the current
reporting trend suggests high under reporting. There
was only total of 304 ADR cases reported during the
year 2006 to 2009 by four RPCs [14]. Therefore, the pur-
pose of this study is to investigate the knowledge and
attitudes of healthcare professionals to report ADR wor-
king at four RPCs of Nepal and to suggest possible ways
to improve the ADR reporting based on the findings.
The findings of knowledge about ADR and ADR repor-
ting among healthcare professionals will be presented
elsewhere.
Methods
Study design and setting
This study was conducted in the four RPCs of Nepal.
The four RPCs were Manipal Teaching Hospital (MTH),
Pokhara, Tribhuvan University Teaching Hospital
(TUTH), Kathmandu, Nepal Medical College Hospital
(NMCH), Kathmandu and KIST Medical College Hospital
(KISTMCH), Lalitpur. All those RPCs are teaching hos-
pital in nature.
A cross sectional study was done by survey using a
self-administered structured questionnaire. The atti-
tude components of the questionnaire are presented
in Additional file 1. There were 450 self-administered
structured questionnaires distributed to all potential
healthcare professionals (doctors, nurses and pharmacists)
working at four RPCs. The questionnaire was structured
to obtain the demographics of healthcare professionals,
factors discouraging ADR reporting, factors that they per-
ceived may influence reporting, ways to improve ADR
reporting and feedbacks they would like to receive from
NPC. Questionnaire was designed to five level likert scale
(1 = strongly disagree and 5 = strongly agree) and single
choice. The questionnaire was attached with the covering
letter, which had aimed to provide the information of the
research to the participants. The participant information
sheet contained the objective of the research, the number
of participants expected to include in the research, theway to response the questionnaire, their right to decide
about whether or not to participate in the research and
confidentiality of the response. The questionnaire so de-
signed was tested for content validity by consensus of the
expert’s panel comprising Prof. Ralph Edwards and Assist.
Prof. Pramote Tragulpiankit. Objectivity test was done by
distributing to 10 of the principal investigator’s colleagues
and instructors of Mahidol University, Bangkok, Thailand.
The comments made were incorporated and question-
naire was modified accordingly. Finally, pilot study was
conducted at two hospitals of Nepal, which were Alka
Hospital Pvt. Ltd., Lalitpur and Civil Service Hospital,
Kathmandu, for the reliability of the questionnaire. There
were 50 questionnaires randomly distributed among doc-
tors, nurses and pharmacists working at two hospitals. The
reliability of the questionnaire was evaluated by calculating
Cronbach alpha. The alpha score for the attitudes towards
ADR was calculated 0.81 and was considered good.
Data collection
The self-administered structured questionnaires were
distributed among healthcare professional through dif-
ferent departments of the four RPCs. The first response
was collected within 3 weeks of the distribution. After
that reminder was sent to all respondents with apologize
to the ones who have already answered the question-
naire. The second response was collected within 3 weeks
of the reminder. Targeted follow up was also done after
this reminder to the respondents by personal visit or
telephone call. This study was approved by Mahidol
University, Faculty of Dentistry/ Faculty of Pharmacy,
Institutional Review Board (MU-DT/PY-IRB) and, Ins-
titutional Review Board of the four hospitals before
starting the data collection.
Statistical analysis
The SPSS statistical programme for Windows, version
17.0 was used for the analysis of the data. The coded
data was systematically verified and checked for errors.
Results were presented as mean ± standard deviation for
quantitative variables and number with percentage or
graphic presentation for categorical variables, where ap-
plicable. Percentage on each category, median and mode
was presented for the likert scale. The chi-square test
was performed to find out the association between ADR
occurrence and ADR reporting among healthcare pro-
fessionals. The comparison of the attitudes among differ-
ent category of healthcare professionals was analyzed by
Kruskal Wallis test. Significance level of P < 0.05 was
used, where the test was relevant.
Results
Out of 450 questionnaires distributed, 333 were received
back with an overall response rate of 74.0%. There were
Table 1 Demography details and characteristic features
of the respondents
Category Sub-category Number (%)
Gender Male 128 (38.4)
Female 201 (60.4)
Data missing 4 (1.2)









Data missing 6 (1.8)
Professional qualification Doctor 162 (48.6)
Nurse 135 (40.5)
Pharmacist 32 (9.6)
Data missing 4 (1.2)











Data missing 16 (4.8)
Category Sub-category* Number (%)




Nurse MN 2 (0.6)
BN 36 (10.8)
PCL 97 (29.1)
Pharmacist PhD and Master 9 (2.7)
BPharm 6 (1.8)
PCL/Diploma 17 (5.1)
Country of undergraduate study Nepal 163 (75.8)
India 26 (12.1)
Bangladesh 11 (5.1)
Table 1 Demography details and characteristic features





Data missing 6 (2.8)
*Note: MD: Doctor of medicine, MS: Master of surgery, MBBS: Bachelor of
medicine and surgery, MDS: Master of dental surgery, BDS: Bachelor of dental
surgery, MN: Master in nursing, BN: Bachelor in nursing, PCL: Proficiency
certificate level, PhD: Doctor of Philosophy, BPharm: Bachelor of Pharmacy.
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did not mention about their gender and profession.
There were 162 doctors, 135 nurses and 32 pharmacists.
Among the respondents, 66.4% were in the age group
21–30 years and 67.9% of them had experiences of
1–5 years followed by 13.2% who had experiences of
6–10 years. The mean age and the experience were
29.5 years and 5.4 years, respectively. The characteris-
tic features of the respondents are shown in Table 1.
Two hundred and forty six healthcare professionals
(74.8%) had seen patient experiencing an ADR. Among
them, 82.7% of doctors, 67.4% of nurses and 65.6% of
pharmacists had seen ADR during their routine work
(P = 0.005). In contrast, only 66 respondents (20.1%) had
ever reported an ADR to the pharmacovigilance centre/
unit of their hospital. There were 21.6% of doctors,
17.0% of nurses and 25.0% of pharmacists who had ever
reported ADR (P = 0.440). The details are shown in
Table 2. There were 38.3% of doctors, 40.7% of nurses,
and 28.1% of pharmacists provided reasons for ADR not
reported. Among the respondents, 28.4% of doctors,
26.7% of nurses, and 9.4% of pharmacists were unaware
about the existence of PV centre/unit in the hospital.
Two hundred and forty five respondents (75.6%) agreed
(score 4 or 5 on the likert scale) on seriousness of the re-
action, 230 (71.2%) agreed on reaction to new product,
226 (70.2%) agreed on new reaction to existing product,
208 (64.6%) agreed on unusual reaction, and 196 (60.8%)
agreed on confidence in diagnosis of ADR as an important
factors on the decision to report ADR. In contrast, ADR
reporting form not available 155 (48.1%) and other col-
leagues not reporting ADR cases 151 (46.9%) were the
major discouraging factors. Among the respondents, 167
(51.8%) disagreed (score 1 or 2 on the likert scale) on
ADR reporting as a guilt of causing patient harm and 165
(51.2%) disagreed on ambition to publish case report per-
sonally as a factor discouraging ADR reporting. Similarly,
151 (46.9%) disagreed on ADR reporting will generate
extra work, 141 (43.8%) disagreed on fear of legal liability,
141 (43.8%) disagreed on belief of only safe drugs are
marketed, and 129 (40.1%) disagreed on lack of time to ac-
tively look for an ADR (Table 3).
Table 2 Experience of ADR occurrence and ADR reporting among healthcare professionals
Category Profession Yes (%) No (%) P-value*
Even seen any patient experiencing an ADR Total 246 (74.8) 83 (25.2)
Doctor 134 (82.7) 28 (17.3) P=0.005
Nurse 91 (67.4) 44 (32.6)
Pharmacist 21 (65.6) 11 (34.4)
Ever reported an ADR to the Pharmacovigilance
Centre/ Unit of his/her hospital
Total 66 (20.1) 263 (79.9)
Doctor 35 (21.6) 127 (78.4) P=0.440
Nurse 23 (17.0) 112 (83.0)
Pharmacist 8 (25.0) 24 (75.0)
* Chi-square test.
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gested awareness among healthcare professionals, training
for healthcare professionals 253 (76.0%), collaboration
among other healthcare professionals 223 (67.0%), involve
pharmacists for ADR reporting 210 (63.1%), and make
reporting a professional obligation 184 (55.5%) as a pos-
sible ways to improve ADR reporting in the context of
Nepal. Majority of the respondents would like to receive
feedbacks from the national pharmacovigilance program-
me. The identified mode of feedbacks were regular news-
letter on current awareness on drug safety 237 (71.2%),
information of new ADR by newsletter 219 (65.8%), inter-
national drug safety information 213 (64.0%), annual na-
tional statistics 196 (58.9%), and individual response to
report 146 (43.8%).
Discussion
This study identified the attitudes towards ADR and
ADR reporting among healthcare professionals workingTable 3 Factors discouraging ADR reporting
Factors n Respo
1a
Concern that the report may be wrong 323 68 (21
Lack of time to fill in a report and a single unreported
case may not affect ADR database
322 65 (20
Not confident to decide whether or not an ADR has occurred 322 72 (22
Lack of time to actively look for an ADR while at work 322 74 (23
Fear of legal liability by reporting adverse reaction 322 87 (27
Concern that a report will generate an extra work 322 97 (30
Belief that only safe drugs are marketed 322 74 (23
Think that you may have caused a patient harm 322 99 (30
Ambition to publish case report personally 322 99 (30
Reporting forms are not available when needed 322 40 (12
Other colleagues are not reporting ADR cases 322 54 (16
a 1 = strongly disagree.
b 2 =moderately disagree.
c 3 = neutral.
d 4 =moderately agree.
e 5 = strongly agree.
* More than one mode exists, the lowest is presented.at four RPCs of Nepal. Among six RPCs, we did not in-
clude two RPCs in this study as they recognized after
this study was started. This study found that healthcare
professionals have positive attitudes towards ADR and
ADR reporting. The overall response rate of 74.0% was
acceptable. The higher percentage of female respondents
compared to male is because of nurses as a segmented
group included in this research. Nursing practitioners in
Nepal are female only. While looking at experiences and
ages of the respondents, mostly the young and beginner
healthcare professionals were participated in this re-
search. In Nepal, the clinical role of pharmacist is in
infancy, mostly involved in dispensing and counseling,
rather than direct pharmaceutical care. Two hundred
and six healthcare professionals participated in this re-
search had only first degree qualification to practice.
One hundred and sixty three had perused the qualification
in Nepal. In the curricula of Bachelor of Medicine and
Surgery (MBBS) and Bachelor of Pharmacy (BPharm) innse (%) Median Mode
2b 3c 4d 5e
.1) 58 (18.0) 85 (26.3) 64 (19.8) 48 (14.9) 3.0 3
.2) 54 (16.8) 86 (26.7) 74 (23.0) 43 (13.4) 3.0 3
.4) 48 (14.9) 91 (28.3) 70 (21.7) 41 (12.7) 3.0 3
.0) 55 (17.1) 77 (23.9) 70 (21.7) 46 (14.3) 3.0 3
.0) 54 (16.8) 88 (27.3) 51 (15.8) 42 (13.0) 3.0 3
.1) 54 (16.8) 87 (27.0) 56 (17.4) 28 (8.7) 3.0 1
.0) 67 (20.8) 74 (23.0) 66 (20.5) 41 (12.7) 3.0 1*
.7) 68 (21.1) 76 (23.6) 46 (14.3) 33 (10.2) 2.0 1
.7) 66 (20.5) 89 (27.6) 39 (12.1) 29 (9.0) 2.0 1
.4) 46 (14.3) 81 (25.2) 71 (22.0) 84 (26.1) 3.0 5
.8) 43 (13.4) 74 (23.0) 79 (24.5) 72 (22.4) 3.0 4
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equately covered. However, as a part of MBBS course in
some institutions students are trained to ADR reporting
and causality assessments [15]. But in UK, majority of the
medical schools have included yellow card scheme in the
undergraduate syllabuses and most of them assess student
knowledge on the scheme [16]. The healthcare profes-
sionals, doctors, nurses and pharmacists, are the main re-
porter of the ADR case which they encountered on their
routine work in general; however, involvement of nurses
as a reporter is not well accepted by hospital physicians
[17]. In Nepal, nurses are allowed to report ADR; however,
they are not encouraged enough to report.
Different studies reported that all the ADRs encoun-
tered by healthcare professionals during their work are
never reported [8,11,17-19], even though, majority of
them felt ADR reporting is important in principle. This
study also showed the same trend in terms of ADR en-
countered and ADR reporting. Two hundred and forty
six (74.8%) healthcare professionals who had seen pa-
tient experiencing an ADR. However, only 66 (20.1%) of
them had reported to the pharmacovigilance centre/unit
of their hospital. But in the countries where ADR moni-
toring system is well established for example UK, France,
Netherland and Sweden the ADR reporting rates among
physicians estimate 40–70% [6-8,17,20]. This might be
because ADR reporting is mandatory in all those coun-
tries. In 2006, the reporting rate in Sweden was 563 per
million inhabitants [17]. The main reason for not repor-
ted ADR cases in this study were healthcare professio-
nals did not know about existence of pharmacovigilance
centre/unit in their hospitals. The other reasons for not
reporting ADR were, reactions were not serious, did not
know how to report, reported to concern doctors, did
not think necessary to report.
This study showed positive attitudes to ADR reporting
among healthcare professionals working at four RPCs of
Nepal. Out of 11 discouraging factors to report ADR
provided to rate, most had neutral response. The median
of 9 factors was 3. Due to lack of practice of ADR re-
porting most of the respondents might have chosen
neutral response. We found that reporting form not
available and other colleagues not reporting ADR cases
would significantly influence the ADR reporting among
healthcare professional. Reporting form not available
identified as a discouraging factor to report ADRs by
other studies too [19,21,22]. On the other hand, lack of
time to actively look for an ADR while at work, fear of
legal liability, ADR reporting will generate extra work,
belief of only safe drugs are marketed, think that they
may have caused patient harm and ambition to publish
case report personally were not significant factors to dis-
courage ADR reporting among healthcare professionals.
Even though, 119 (36.0%) of the healthcare professionalsagreed on lack of time to actively look for an ADR while
at work and 107 (33.2%) believed that only safe drug are
marketed. This is suggestive for train healthcare profes-
sionals by including ADR reporting and causality assess-
ment in undergraduate syllabuses. This study showed
that healthcare professionals working at four RPCs per-
ceived that seriousness of the reaction, unusual reaction,
reaction to new product, new reaction to existing prod-
uct and, confidence in diagnosis of ADR are important
factors on the decision to report ADR. Seriousness, un-
usual reaction, reaction to new product and certainty
were also identified as important factors to report ADR
among physicians in different studies [7,8,17,18].
Awareness among healthcare professionals, collabor-
ation among other healthcare professionals and training
for healthcare professionals were the highly suggested
ways to improve ADR reporting. Healthcare professio-
nals believed that making ADR reporting, a professional
obligation and involved pharmacists for ADR reporting
can also improve ADR reporting. Previous studies have
also identified ADR reporting as a professional obliga-
tion [21,23]. In some countries for example Sweden,
France, ADR reporting by healthcare professionals is
compulsory, even though, the impact to counter under-
reporting is still controversial [24]. ADR reporting as
a professional obligation will have moral binding to
healthcare professionals and ethical issues. Studies have
shown that pharmacist involvement can improve the
number and quality of ADR reports along with subs-
tantial role in maintenance of drug safety monitoring
programme [25-27]. The feedbacks they would like to
receive from the national pharmacovigilance programme
as regular newsletters on current awareness in drug
safety, information on new drug adverse reactions by
newsletters, annual national statistics and international
drug safety information can be incorporate in a single
newsletter. DDA is publishing Drug Bulletin of Nepal
(BDN) on a regular basis [28]. The scope of the bulletin
is wide. It can be updated with a regular column related
to national and international drug safety information,
even though; it has regular information related to cur-
rent awareness in drug safety. The feedback from the
national centre ensures two way communications be-
tween healthcare professionals and the national centre.
In Sweden, feedback letters along with result of causality
assessment of the reported ADR case is sent to the re-
porter concerned [17]. This is supposed to be one of the
possible reasons of the high reporting rate in Sweden
and elsewhere.
There are some limitations of this study. First, the sam-
ple does not represent the whole population of healthcare
professionals of Nepal as it was conducted only on the
four RPCs of Nepal, where the ADR monitoring is already
in place. Second, questionnaires were distributed through
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aid of relevant books/publications or contemporary col-
leagues could not be excluded.
Conclusion
This study showed that healthcare professionals working
at four RPCs of Nepal have positive attitudes about ADR
reporting; however, the reporting culture is not well de-
veloped as reflected by the huge gap between the ADR
encountered and ADR reporting trend among healthcare
professionals. The unavailability of ADR reporting form
and colleague’s negative reporting nature are significantly
discouraging them to report ADRs. However, awareness
among healthcare professionals, training and collaboration
would likely improve ADR reporting provided they would
receive appropriate feedbacks from the national pharma-
covigilance programme preferably as regular newsletter
on current awareness in drug safety, information on new
ADR and international drug safety information.
Additional file
Additional file 1: Questionnaire for evaluating healthcare
professionals’ attitudes towards ADR reporting in Nepal.
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